Clinical trial: Semaglutide lowers cardiovascular events in adults who are overweight or obese but do not have diabetes by 20%.

Published Date: 15 Nov 2023

According to a doctor at Cleveland Clinic, semaglutide decreased cardiovascular events in adults with established cardiovascular disease who were overweight or obese by 20 percent. These findings came from a multi-center, international clinical trial.

Read Full News

Latest News

Study shows Ozempic could help dialysis patients qualify for kidney transplants

Obesity is one of the biggest barriers preventing patients with end-stage kidney disease from receiving a life-saving kidney transplant. New research from Saint Louis University School of Medicine and SSM Health physicians ...

How do I know if my kid is worrying about food and their body too much? And what should I say?

Eating disorders are most likely to develop in young people aged between 12 and 25.

Understudied eating disorder matches anorexia, bulimia severity

A diagnosis often viewed as less serious than anorexia and bulimia—and the most common eating disorder worldwide—can cause just as much harm, a new study has found.

Popular weight-loss drugs show added heart protection for diabetes patients

Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes. Researchers at the Technical University of Munich (TUM) and Harvard Medical School have demonstrated this ...

Diabetes drug reduced irregular heartbeat events in overweight/obese adults with AFib

People with atrial fibrillation (AFib) and obesity may have fewer episodes of AFib after ablation if they take the diabetes medication metformin in addition to standard care, according to a preliminary, late-breaking science ...

Mandatory nutrient warning labels could prevent 100,000+ obesity-related deaths

Researchers from the University of Liverpool have found that making front-of-pack nutrition labeling mandatory could significantly reduce obesity rates and save thousands of lives across England.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Latest News

Obesity is one of the biggest barriers preventing patients with end-stage kidney disease from receiving a life-saving kidney transplant. New research from Saint Louis University School of Medicine and SSM Health physicians ...

Eating disorders are most likely to develop in young people aged between 12 and 25.

A diagnosis often viewed as less serious than anorexia and bulimia—and the most common eating disorder worldwide—can cause just as much harm, a new study has found.

Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes. Researchers at the Technical University of Munich (TUM) and Harvard Medical School have demonstrated this ...

People with atrial fibrillation (AFib) and obesity may have fewer episodes of AFib after ablation if they take the diabetes medication metformin in addition to standard care, according to a preliminary, late-breaking science ...

Researchers from the University of Liverpool have found that making front-of-pack nutrition labeling mandatory could significantly reduce obesity rates and save thousands of lives across England.

News All Time

Five reasons we shouldn't 'compliment' people who lose weight

"You look so great! Have you lost weight?"

Nearly 70% of US adults meet new definition of obesity, study finds

The prevalence of obesity in the United States could rise sharply under a definition of obesity released earlier this year by the Lancet Diabetes and Endocrinology Commission.

BMI shouldn't be the only way to assess who can access weight-loss drugs

About 1 in 3 Australian adults (32%) has a body-mass index (BMI) of 30 or above. A further 34% has a BMI of 25 or above.

Diets high in ultra-processed foods are bad for us, so why are we eating more?

Aussies eat more ultra-processed foods than ever before, with busy lifestyles and personal choices often taking the blame as casual factors.

Weight loss drug stigma shows society still holds negative attitudes towards body weight and obesity

Since Wegovy received approval as a weight loss treatment in 2021, there has been huge demand for GLP-1 drugs. These drugs reduce hunger and suppress the "food noise" that can make it difficult to lose weight.

Two in three people with chronic pain turn to comfort eating

More than two-thirds of people living with chronic pain reach for chocolate or other comfort foods to cope, with new research showing that eating offers pleasure, distraction and relief from negative emotions during pain ...

Gaps and opportunities in precision medicine approach to obesity treatment identified

A new report led by researchers at Pennington Biomedical Research Center underscores the growing potential of precision medicine to transform how obesity is prevented, diagnosed and treated, while also illuminating key gaps ...

Think your BMI reflects your health? Think again, study warns

As new Statistics Canada data reveals that two-thirds of Canadians are considered overweight or obese, researchers are urging the public and policymakers to rethink how we define and measure health—starting with one of ...

Use of weight loss drugs before bariatric surgery has soared in recent years, study finds

New research findings show a significant increase in the use of weight loss drugs among patients undergoing metabolic and bariatric surgery, signaling an evolution in the management of obesity and type 2 diabetes.

Research highlights the need for culturally specific screening tools

Despite research finding a higher prevalence of eating disorders among Aboriginal youth in Australia, new research from Edith Cowan University (ECU) published in the Journal of Eating Disorders has revealed a lack of culturally ...

Semaglutide, tirzepatide recommended as first-line treatment of obesity and most of its complications in new guidance

Semaglutide or tirzepatide should be the first line treatment for people living with obesity and most of its complications, according to a new framework for the pharmacological treatment of obesity and its complications from ...

Weight-loss surgery could help boost work productivity

A new international QUT-led study found that bariatric surgery improves work productivity and employment rates in the short term—but these gains may not last beyond five years without targeted support.

Reducing risk of eating disorders by controlling peer and family pressures

Weight-related peer teasing is a strong predictor of disordered eating behaviors in adolescents, particularly those at higher genetic risk, new research shows.

Study suggests new drug for weight loss may cause fewer side effects

A new Penn Nursing study suggests that the weight-loss drug tirzepatide may cause fewer side effects like nausea and vomiting than the drug semaglutide. This research, published in Science Advances, was conducted using preclinical ...

Weight loss treatments for people with diabetes and obesity could lower the risk of obesity-related cancers

Weight loss treatments, including medication and surgical procedures, may help lower the risk of obesity-related cancers in people with obesity and type 2 diabetes, a new study shows.

Too heavy for medical care: Over 40% of specialty clinics turn away patients weighing 465 pounds

Patients weighing 450 pounds or more face barriers and discrimination when scheduling or attending doctor visits at subspecialty practices, reports a new Northwestern Medicine study.

Recommended News For You

In KRAS-mutated non-small cell lung cancer, glecirasib exhibits promising efficacy.

Radioligand Therapy Set to Transform Oncology Care

Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk

Women are more susceptible to the stress caused by inflation.

Ultrasound imaging of breast cancer tumors offers noninvasive monitoring of treatment effectiveness

Waist circumference outshines BMI as obesity-related cancer risk marker in men, but not women

Women who miss their first mammogram face higher risk of breast cancer death, study finds

Recommended Articles For You

Mechanisms, Efficacy, and Survival Outcomes in AML, Squamous Cell Carcinoma, & Non-Hodgkin Lymphoma 

Phosphate Vs. Phosphorus: What Is The Difference? 

What Is A Normal Fibrinogen Level, And How Can It Affect Your Health 

Understanding Colon Cancer: Symptoms, Causes, and Treatment Options  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Psychedelic Therapy Tied to Reduced Depression, Anxiety.

2.

New drug resistance mechanism in melanoma leptomeningeal disease revealed by study.

3.

Research finds stark disparities in treatment and survival time for people with pancreatic cancer

4.

Tumor characteristics found to differ for melanomas in children, teens and young adults

5.

Relationship-building key to addressing oncologist shortages in rural care

1.

Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook

2.

Colon cancer: Risk factors, warning signs and treatment options 

3.

Exploring the Latest Advances in Hodgkin's Lymphoma Treatment

4.

Can We Repurpose BV-CHP for Better Outcomes in Peripheral T-Cell Lymphoma?

5.

The Expanding Horizon of PSMA: A Comparative Clinical Review of Theranostics in Prostate Cancer and Beyond

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC

2.

Efficient Management of First line ALK-rearranged NSCLC - Part VIII

3.

Evolution in Treatment and Diagnosis of Lung Cancer- An Initiative from Manipal Hospitals

4.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V

5.

INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot